[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 37 of about 37
1. Tafe LJ, Garg K, Chew I, Tornos C, Soslow RA: Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently underrecognized neoplasms. Mod Pathol; 2010 Jun;23(6):781-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently underrecognized neoplasms.
  • Carcinomas of the endometrium and ovary with undifferentiated components are uncommon neoplasms that are likely underdiagnosed.
  • We identified 32 carcinomas with undifferentiated components as defined by Silva and co-workers, 26 endometrial and 6 of ovarian origin.
  • Most patients (58% of endometrial and 83% of ovarian carcinomas with undifferentiated components) presented at advanced stages (FIGO III-IV).
  • Twenty tumors, entirely undifferentiated, consisted of sheets of dyshesive, ovoid cells with uniform, large vesicular nuclei, whereas 12 tumors contained combinations of differentiated endometrioid adenocarcinoma with undifferentiated components.
  • Although most undifferentiated tumors had a monotonous cytologic appearance without prominent stroma, six showed focal nuclear pleomorphism and eight cases had variably sized zones of rhabdoid cells in a background of myxoid stroma.
  • Endometrial and ovarian carcinomas with undifferentiated components have a broad histologic differential diagnosis, but they show specific histologic features that should enable accurate diagnosis.
  • [MeSH-major] Carcinoma / pathology. Cell Differentiation. Endometrial Neoplasms / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20305618.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


2. Bakar B, Tekkök IH: Primary undifferentiated ovarian carcinoma diagnosed by its metastasis to brain: an unusual case report. Turk Neurosurg; 2008 Oct;18(4):431-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary undifferentiated ovarian carcinoma diagnosed by its metastasis to brain: an unusual case report.
  • OBJECTIVES: Intracranial metastasis of ovarian tumours is rarely seen with an incidence 0.1- 5% but simultaneous diagnosis of primary undifferentiated carcinoma of the ovary and its CNS metastasis has not been published previously.
  • A right ovarian mass measuring 100x85x135 mm was discovered with abdominal ultrasound.
  • The histopathological diagnosis was undifferentiated ovarian carcinoma which dedifferentiated from endometrioid-type ovarian adenocarcinoma.
  • CONCLUSIONS: Although metastasis from undifferentiated ovarian carcinomas to the central nervous system have been published with the CNS disease often developing long after the initial diagnosis of primary tumour; simultaneous diagnosis of primary undifferentiated carcinoma of the ovary and its CNS metastasis as described in our case may rarely occur.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / secondary. Carcinoma / diagnosis. Carcinoma / pathology. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19107695.001).
  • [ISSN] 1019-5149
  • [Journal-full-title] Turkish neurosurgery
  • [ISO-abbreviation] Turk Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


3. Prat J: Ovarian carcinomas, including secondary tumors: diagnostically challenging areas. Mod Pathol; 2005 Feb;18 Suppl 2:S99-111
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian carcinomas, including secondary tumors: diagnostically challenging areas.
  • The differential diagnosis of ovarian carcinomas, including secondary tumors, remains a challenging task.
  • Mucinous carcinomas of the ovary are rare and can be easily confused with metastatic mucinous carcinomas that may present clinically as a primary ovarian tumor.
  • International Federation of Gynecology and Obstetrics (FIGO) stage is the single most important prognostic factor, and stage I carcinomas have an excellent prognosis; FIGO stage is largely related to the histologic features of the ovarian tumors.
  • Metastatic colon cancer is frequent and often simulates ovarian endometrioid adenocarcinoma.
  • Transitional cell carcinomas are distinguished from undifferentiated carcinomas by the presence of thick, undulating papillae with smooth luminal borders, microspaces, and tumor cells with distinctive 'urothelial' appearance.
  • Krukenberg tumors are metastatic adenocarcinomas traditionally perceived as composed of mucin-filled signet-ring cells associated with a striking proliferation of the ovarian stroma but many variations on this pattern occur.
  • [MeSH-major] Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15492758.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CTNNB1 protein, human; 0 / Cytoskeletal Proteins; 0 / Intermediate Filament Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 0 / Trans-Activators; 0 / beta Catenin; 68238-35-7 / Keratins; EC 3.6.5.2 / ras Proteins
  • [Number-of-references] 63
  •  go-up   go-down


Advertisement
4. Gallagher MF, Flavin RJ, Elbaruni SA, McInerney JK, Smyth PC, Salley YM, Vencken SF, O'Toole SA, Laios A, Lee MY, Denning K, Li J, Aherne ST, Lao KQ, Martin CM, Sheils OM, O'Leary JJ: Regulation of microRNA biosynthesis and expression in 2102Ep embryonal carcinoma stem cells is mirrored in ovarian serous adenocarcinoma patients. J Ovarian Res; 2009;2:19
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulation of microRNA biosynthesis and expression in 2102Ep embryonal carcinoma stem cells is mirrored in ovarian serous adenocarcinoma patients.
  • BACKGROUND: Tumours with high proportions of differentiated cells are considered to be of a lower grade to those containing high proportions of undifferentiated cells.
  • In this study we assessed microRNA (miRNA) regulation in two populations of malignant Embryonal Carcinoma (EC) stem cell, which differentiate (NTera2) or remain undifferentiated (2102Ep) during tumourigenesis, and compared this to miRNA regulation in ovarian serous carcinoma (OSC) patient samples.
  • METHODS: miRNA expression was assessed in NTera2 and 2102Ep cells in the undifferentiated and differentiated states and compared to that of OSC samples using miRNA qPCR.
  • In the undifferentiated state 2102Ep cells expressed mature miRNAs at up to 15,000 fold increased levels despite decreased expression of miRNA biosynthesis genes Drosha and Dicer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] PLoS Pathog. 2009 Apr;5(4):e1000389 [19381257.001]
  • [Cites] J Gastroenterol Hepatol. 2009 Apr;24(4):652-7 [19175831.001]
  • [Cites] Cancer Res. 2009 Apr 15;69(8):3356-63 [19351832.001]
  • [Cites] J Biol Chem. 2009 Apr 24;284(17):11326-35 [19251704.001]
  • [Cites] PLoS One. 2009;4(3):e4998 [19308264.001]
  • [Cites] Nucleic Acids Res. 2009 Apr;37(5):1672-81 [19153141.001]
  • [Cites] Oncology. 2009;76(3):162-9 [19209007.001]
  • [Cites] J Biol Chem. 2009 Feb 27;284(9):5731-41 [19073608.001]
  • [Cites] Cancer Gene Ther. 2009 Mar;16(3):206-16 [18949015.001]
  • [Cites] Clin Cancer Res. 2009 Feb 15;15(4):1177-83 [19228723.001]
  • [Cites] Cell Cycle. 2009 Jan 1;8(1):158-66 [19158483.001]
  • [Cites] Free Radic Biol Med. 2009 Jan 15;46(2):282-8 [19022373.001]
  • [Cites] J Ovarian Res. 2008;1:8 [19025622.001]
  • [Cites] N Engl J Med. 2008 Dec 18;359(25):2641-50 [19092150.001]
  • [Cites] Cancer Res. 2008 Dec 15;68(24):10307-14 [19074899.001]
  • [Cites] Eur J Cancer Prev. 2009 Feb;18(1):50-5 [19077565.001]
  • [Cites] Gynecol Oncol. 2008 Dec;111(3):478-86 [18823650.001]
  • [Cites] Nature. 2008 Dec 4;456(7222):593-8 [19052619.001]
  • [Cites] RNA. 2008 Nov;14(11):2348-60 [18812439.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1124-8 [18806776.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Nov 7;376(1):86-90 [18765229.001]
  • [Cites] BMC Med. 2008;6:15 [18577221.001]
  • [Cites] BMC Med. 2008;6:14 [18577219.001]
  • [Cites] PLoS One. 2008;3(6):e2436 [18560586.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 May 13;105(19):7004-9 [18458333.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2588-92 [18451220.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2690-5 [18451233.001]
  • [Cites] J Biol Chem. 2008 May 9;283(19):13205-15 [18319255.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3903-8 [18308936.001]
  • [Cites] Oncogene. 2008 Mar 13;27(12):1788-93 [17891175.001]
  • [Cites] Cell. 2008 Mar 7;132(5):875-86 [18329372.001]
  • [Cites] Cancer Res. 2008 Mar 1;68(5):1362-8 [18316599.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Cell. 2008 Feb 22;132(4):563-6 [18295575.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1608-13 [18227514.001]
  • [Cites] Nucleic Acids Res. 2008 Jan;36(Database issue):D154-8 [17991681.001]
  • [Cites] Cancer Res. 2008 Jan 1;68(1):26-33 [18172293.001]
  • [Cites] RNA. 2008 Jan;14(1):35-42 [18025253.001]
  • [Cites] Mol Cancer. 2007;6:60 [17894887.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8699-707 [17875710.001]
  • [Cites] Oncogene. 2007 Jun 28;26(30):4442-52 [17237814.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1030-7 [17283135.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):976-83 [17283129.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):973-8 [17210912.001]
  • [Cites] Nucleic Acids Res. 2007 Jan;35(Database issue):D149-55 [17108354.001]
  • [Cites] Nat Genet. 2006 Sep;38(9):1060-5 [16878133.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9 [16849428.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 28;103(13):5078-83 [16549775.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Apr 28;343(1):85-9 [16529715.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10946-51 [16322242.001]
  • [Cites] Biochem Soc Trans. 2005 Dec;33(Pt 6):1526-30 [16246161.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Cancer Res. 1964 Oct;24:1544-51 [14234000.001]
  • [Cites] Lab Invest. 1984 Feb;50(2):147-62 [6694356.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7011-21 [15466194.001]
  • [Cites] J Cell Sci. 2004 Jul 15;117(Pt 16):3539-45 [15226377.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15178-83 [14645703.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Proc Nutr Soc. 2000 Feb;59(1):127-34 [10828182.001]
  • [Cites] BMC Cancer. 2009;9:194 [19538740.001]
  • [Cites] Breast Cancer Res. 2009;11(3):R27 [19432961.001]
  • [Cites] Exp Cell Res. 2009 Sep 10;315(15):2529-38 [19501585.001]
  • [Cites] Hepatology. 2009 Jul;50(1):113-21 [19441017.001]
  • [Cites] J Gastroenterol. 2009;44(6):556-61 [19363643.001]
  • [Cites] Pancreatology. 2009;9(3):293-301 [19407485.001]
  • [Cites] Leuk Lymphoma. 2009 Mar;50(3):506-9 [19347736.001]
  • (PMID = 20015364.001).
  • [ISSN] 1757-2215
  • [Journal-full-title] Journal of ovarian research
  • [ISO-abbreviation] J Ovarian Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2805659
  •  go-up   go-down


5. Miyai K, Yamamoto S, Aida S, Shimazaki H, Takano M, Kudoh K, Furuya K, Tamai S, Matsubara O: Massive intra-abdominal undifferentiated carcinoma derived from an endometrioid adenocarcinoma in a "normal-sized" ovary. Int J Gynecol Pathol; 2010 Jul;29(4):321-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Massive intra-abdominal undifferentiated carcinoma derived from an endometrioid adenocarcinoma in a "normal-sized" ovary.
  • We report a case of massive intra-abdominal undifferentiated carcinoma derived from a tiny well-differentiated endometrioid adenocarcinoma of the ovary.
  • The right ovarian tumor was a histologically well-differentiated endometrioid adenocarcinoma.
  • Both the intra-abdominal undifferentiated tumor and the ovarian adenocarcinoma cells were immunohistochemically positive for keratin AE1/3, Ber-EP4, and CD10.
  • Epithelial membrane antigen was positive only in the ovarian adenocarcinoma component, and vimentin was diffusely positive only in the intra-abdominal undifferentiated tumor component.
  • Allelotype analysis using 24 polymorphic markers located on 12 chromosomal arms showed that the intra-abdominal undifferentiated carcinoma and ovarian adenocarcinoma components had a high concordance rate (88%) of allelic patterns including identical allelic loss patterns at 7 chromosomal loci, suggesting a common genetic lineage.
  • These data suggest that ovarian endometrioid adenocarcinoma, even when small in size, can give rise to a massive undifferentiated carcinoma filling the peritoneal cavity.
  • [MeSH-major] Carcinoma, Endometrioid / secondary. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20567143.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / DNA, Neoplasm; 0 / KRTAP1-3 protein, human; 0 / Keratins, Hair-Specific; 0 / Mucin-1; 0 / S100 Calcium Binding Protein G; 0 / Vimentin; 0 / human epithelial antigen-125; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


6. Pan ZG, Wang B: Anaplastic carcinoma of the pancreas associated with a mucinous cystic adenocarcinoma. A case report and review of the literature. JOP; 2007;8(6):775-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic carcinoma of the pancreas associated with a mucinous cystic adenocarcinoma. A case report and review of the literature.
  • CONTEXT: Anaplastic carcinoma of the pancreas is a rare undifferentiated variant of ductal adenocarcinoma, which commonly displays sarcomatoid spindle-cell and pleomorphic growth patterns.
  • The peri-cystic tissue and the septa consist of an ovarian-type stroma that is strongly positive for CD10.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17993730.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / MUC1 protein, human; 0 / Mucin-1; 0 / Vimentin; 68238-35-7 / Keratins
  • [Number-of-references] 15
  •  go-up   go-down


7. Yasunaga M, Ohishi Y, Nishimura I, Tamiya S, Iwasa A, Takagi E, Inoue T, Yahata H, Kobayashi H, Wake N, Tsuneyoshi M: Ovarian undifferentiated carcinoma resembling giant cell carcinoma of the lung. Pathol Int; 2008 Apr;58(4):244-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian undifferentiated carcinoma resembling giant cell carcinoma of the lung.
  • To date, however, there have been no reported cases of ovarian carcinoma mainly composed of GCC.
  • Herein is reported the case of a 54-year-old Japanese woman with an undifferentiated ovarian carcinoma producing granulocyte colony-stimulating factor (G-CSF) and an inflammatory cytokine.
  • The recognition of this type of ovarian tumor is important for clinical management, because adjuvant chemotherapy is the standard treatment for clinical management of epithelial ovarian cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Giant Cell / diagnosis. Lung Neoplasms / diagnosis. Ovarian Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18324918.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucin-1; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


8. Zhu Y, Brännström M, Janson PO, Sundfeldt K: Differences in expression patterns of the tight junction proteins,claudin 1, 3, 4 and 5, in human ovarian surface epithelium as compared to epithelia in inclusion cysts and epithelial ovarian tumours. Int J Cancer; 2006 Apr 15;118(8):1884-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences in expression patterns of the tight junction proteins,claudin 1, 3, 4 and 5, in human ovarian surface epithelium as compared to epithelia in inclusion cysts and epithelial ovarian tumours.
  • Human ovarian surface epithelium (OSE), regarded as the precursor cell of epithelial ovarian adenocarcinoma, is not a fully developed epithelium when situated on the ovarian surface.
  • Recent gene-expression data on ovarian adenocarcinoma has pointed out a family of TJ proteins, the claudins, to be highly expressed in malignant compared to benign ovarian tumours.
  • The purpose of this study was to investigate the distribution of claudin 1-5 proteins in cultured OSE (n=4), normal ovarian (n=11), benign (n=8), borderline (n=7) and ovarian cancer (n=22) tissues.
  • We found that a weak or absence of expression of claudin 3 and claudin 4 in surface OSE changed to typical cell-border localisation in OSE of inclusion cysts in the normal ovarian stroma.
  • Semiquantitative estimations of immunoblots showed that claudin 3 was significantly increased in ovarian adenocarcinomas compared to benign and borderline-type tumours.
  • Claudin 4 was significantly increased in both borderline-type and ovarian adenocarcinomas compared to benign tumours, whereas no changes were found for claudin 1 or 5.
  • Concerning relation to Federation for International Gynaecology and Obstetrics (FIGO) grade, claudin 3, but not claudin 4, was significantly increased in moderately, poorly and undifferentiated adenocarcinomas compared to well-differentiated and borderline-type tumours.
  • We conclude that both claudin 3 and 4, even though they differ in expression during ovarian malignant transformation, might be used as novel markers for ovarian tumours.
  • [MeSH-major] Adenocarcinoma / genetics. Membrane Proteins / biosynthesis. Ovarian Cysts / genetics. Ovarian Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cysts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16287068.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CLDN1 protein, human; 0 / CLDN3 protein, human; 0 / CLDN4 protein, human; 0 / CLDN5 protein, human; 0 / Claudin-1; 0 / Claudin-3; 0 / Claudin-4; 0 / Claudin-5; 0 / Membrane Proteins
  •  go-up   go-down


9. Kuroda N, Inui Y, Ohara M, Hirouchi T, Mizuno K, Kubo A, Hayashi Y, Enzan H, Lee GH: Hyaline globule-like structures in undifferentiated sarcoma cells of malignant müllerian mixed tumor of the fallopian tube. Med Mol Morphol; 2007 Mar;40(1):46-9
Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyaline globule-like structures in undifferentiated sarcoma cells of malignant müllerian mixed tumor of the fallopian tube.
  • A 57-year-old Japanese woman, after she received a medical checkup, underwent salpingo-oophorectomy on the suspicion of ovarian cancer.
  • The carcinoma showed moderately to poorly differentiated adenocarcinoma.
  • The sarcoma consisted of predominantly undifferentiated sarcoma and focally rhabdomyosarcomatous cells with abundant eosinophilic cytoplasm.
  • Interestingly, the cytoplasm of undifferentiated sarcoma cells contained hyaline globule-like structures.
  • Finally, pathologists should keep in mind that undifferentiated sarcoma cells in MMMT of the fallopian tube may contain hyaline globule-like structures in the cytoplasm.
  • [MeSH-major] Adenocarcinoma / pathology. Fallopian Tube Neoplasms / pathology. Hyalin / ultrastructure. Mixed Tumor, Mullerian / pathology. Rhabdomyosarcoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17384990.001).
  • [ISSN] 1860-1480
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] TDQ283MPCW / Eosine Yellowish-(YS)
  •  go-up   go-down


10. Roblick UJ, Bader FG, Lenander C, Hellman U, Zimmermann K, Becker S, Ost A, Alaiya A, Bruch HP, Keller R, Mirow L, Franzén B, Ried T, Auer G, Habermann JK: Undifferentiated pelvic adenocarcinomas: diagnostic potential of protein profiling and multivariate analysis. Int J Colorectal Dis; 2008 May;23(5):483-91
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Undifferentiated pelvic adenocarcinomas: diagnostic potential of protein profiling and multivariate analysis.
  • MATERIALS AND METHODS: A poorly differentiated adenocarcinoma of unknown origin located in the pelvis, infiltrating the sigmoid colon as well as the ovary, served as a model to evaluate our proteomic approach.
  • Firstly, we characterized the protein expression profiles from eight advanced colon and seven ovarian adenocarcinomas using two-dimensional gel electrophoresis (2-DE).
  • RESULTS: Over 89% of the unknown tumor sample spots could be matched with the colon standard gel, whereas only 63% of the spots could be matched with the ovarian standard.
  • In addition, principal component analysis impressively displayed the clustering of the unknown case within the colon cancer samples, whereas this case did not cluster at all within the group of ovarian adenocarcinomas.
  • CONCLUSION: These results show that 2-DE protein expression profiling combined with principal component analysis is a sensitive method for diagnosing undifferentiated adenocarcinomas of unknown origin.
  • [MeSH-major] Adenocarcinoma / secondary. Cell Differentiation. Colonic Neoplasms / secondary. Neoplasm Proteins / analysis. Neoplasms, Unknown Primary / diagnosis. Ovarian Neoplasms / secondary. Pelvic Neoplasms / diagnosis. Proteomics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18293003.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  •  go-up   go-down


11. Presneau N, Shen Z, Provencher D, Mes-Masson AM, Tonin PN: Identification of novel variant, 1484delG in the 3'UTR of H3F3B, a member of the histone 3B replacement family, in ovarian tumors. Int J Oncol; 2005 Jun;26(6):1621-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of novel variant, 1484delG in the 3'UTR of H3F3B, a member of the histone 3B replacement family, in ovarian tumors.
  • Previous studies have implicated the chromosomal region at 17q25 as harboring tumor suppressor genes based on the frequent loss of heterozygosity (LOH) observed in epithelial ovarian cancers (EOC).
  • In contrast to three other EOC cell lines (TOV81D, TOV112D and TOV21G) and primary cultures derived from normal ovarian surface epithelial cells (NOSE), sequence analysis of the cDNA revealed a deletion of G at position 1484 of the transcribed sequence which is located within the 3'UTR of H3F3B.
  • OV90 was derived from ascites fluid of an undifferentiated adenocarcinoma of ovarian origin.
  • The variant allele was identified in 1 of 65 (2%) healthy women with no prior history of cancer and in 5 participants with ovarian tumors comprising of 4 of 79 (5%) malignant EOC, none of 10 low malignancy potential tumors, and 1 of 8 (13%) benign tumors.
  • The variant allele was identified in EOC samples of clear cell (1 of 20), mucinous (1 of 8), mixed cell (1 of 3) and undifferentiated (1 of 2) histopathological subtypes but none of 34 serous or 12 endometrioid subtype tumors.
  • The functional significance of the variant is unknown, however its presence in rare subtypes of ovarian epithelial tumors warrants further investigation.
  • [MeSH-major] 3' Untranslated Regions / genetics. Histones / genetics. Loss of Heterozygosity. Neoplasms, Glandular and Epithelial / genetics. Ovarian Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15870878.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / 3' Untranslated Regions; 0 / Histones
  •  go-up   go-down


12. Oltmann SC, Fischer A, Barber R, Huang R, Hicks B, Garcia N: Pediatric ovarian malignancy presenting as ovarian torsion: incidence and relevance. J Pediatr Surg; 2010 Jan;45(1):135-9
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric ovarian malignancy presenting as ovarian torsion: incidence and relevance.
  • PURPOSE: With ovarian torsion, concern for underlying malignancy in the enlarged ovary has previously driven surgeons to resection.
  • However, the incidence of malignancies presenting as ovarian torsion is not documented.
  • METHOD: After institutional review board exemption (IRB#-022008-095), a 15(1/2)-year retrospective review was conducted to identify cases of operative ovarian torsion in our medical center.
  • RESULTS: A total of 114 patients (mean +/- SEM age, 10 years, 2 days to 19 years +/- 0.53) with operatively proven ovarian torsion were identified.
  • The literature yielded a total of 593 cases of operative ovarian torsion with 9 (1.5%) malignancies and 193 (33%) benign neoplasms.
  • The malignancies were juvenile granulosa cell tumor (n = 4), dysgerminoma (n = 2), serous borderline tumors (n = 2), and 1 undifferentiated adenocarcinoma.
  • CONCLUSION: By combining our series with 13 in the literature, a 1.8% malignancy rate occurred in 707 patients with ovarian torsion, markedly less than the reported malignancy rate of 10% in children with ovarian masses.
  • These data further support the implementation of operative detorsion and close postoperative ovarian surveillance, with reoperation for persistent masses.
  • [MeSH-major] Ovarian Diseases / diagnosis. Ovarian Neoplasms / diagnosis. Torsion Abnormality / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / surgery. Adolescent. Adult. Age Factors. Child. Child, Preschool. Diagnosis, Differential. Dysgerminoma / diagnosis. Dysgerminoma / surgery. Female. Granulosa Cell Tumor / diagnosis. Granulosa Cell Tumor / surgery. Humans. Incidence. Infant

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20105593.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 20
  •  go-up   go-down


13. Dundr P: [Ovarian carcinoma: current diagnostic principles]. Cesk Patol; 2010 Jul;46(3):53-61
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ovarian carcinoma: current diagnostic principles].
  • Ovarian cancer is the most common cause of death from a gynecologic cancer.
  • The most common types of ovarian cancer are carcinomas of surface epithelial-stromal origin.
  • Ovarian carcinomas are a heterogeneous group of neoplasms.
  • Type I tumors include low-grade serous adenocarcinoma, low-grade endometrioid adenocarcinoma, mucinous adenocarcinoma, malignant Brenner tumor and some clear cell carcinomas.
  • Type II tumors are high-grade neoplasms including undifferentiated carcinoma, high-grade serous adenocarcinoma, high-grade endometrioid adenocarcinoma, malignant mixed Müllerian tumor and probably some clear cell carcinomas.
  • At present, the histological type of ovarian carcinoma has only limited impact on the management of these tumors.
  • However, with progress towards the type-specific treatment of ovarian carcinoma, accurate histopathological diagnosis of ovarian carcinoma becomes increasingly important.
  • In this review we summarize recent advances in the histopathological diagnosis of ovarian carcinoma.
  • Moreover, we mention genetic changes in different types of ovarian carcinoma.
  • [MeSH-major] Ovarian Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20941958.001).
  • [ISSN] 1210-7875
  • [Journal-full-title] Československá patologie
  • [ISO-abbreviation] Cesk Patol
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Czech Republic
  •  go-up   go-down


14. Silva EG, Deavers MT, Bodurka DC, Malpica A: Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma? Int J Gynecol Pathol; 2006 Jan;25(1):52-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma?
  • The association of this type of tumor with undifferentiated carcinoma is rare.
  • Undifferentiated carcinoma associated with low-grade endometrioid carcinoma was found at presentation in 19 grade 1 or 2 endometrioid carcinomas: 15 in the endometrium and 5 in the ovary.
  • In one of these cases, undifferentiated carcinoma was found in the endometrium and the ovary.
  • Undifferentiated carcinoma was found after resection of low-grade endometrioid carcinoma in six cases, involving the retroperitoneum, pelvis, vagina, or liver.
  • The undifferentiated carcinoma was composed exclusively of diffuse sheets and solid nests of epithelial cells in l0 cases.
  • Foci of undifferentiated carcinoma may be confused with solid endometrioid adenocarcinoma erroneously leading to the diagnosis of a grade 3 or a significantly less aggressive grade 2 endometrioid carcinoma.
  • The recognition of undifferentiated carcinoma in an otherwise low-grade endometrioid adenocarcinoma is extremely important because it indicates aggressive behavior.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Cell Transformation, Neoplastic. Endometrial Neoplasms / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Int J Gynecol Pathol. 2006 Jul;25(3):304
  • (PMID = 16306785.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


15. Stevenson MM, Mostertz W, Acharya C, Walters K, Barry W, Tuchman S, Ready N, Onaitis M, Crawford J, Potti A: Characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):11001

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma.
  • METHODS: Using a large cohort of lung cancer cell lines with associated gene expression data, genes associated with an embryonic stem cell identity were used to develop a 'signature' representative of embryonic stemness (ES) activity specific to lung adenocarcinoma.
  • The ES signature was applied to three independent early (stage I - IIIa) lung adenocarcinoma data sets (N = 634) with clinically annotated gene expression data.
  • RESULTS: Using Bayesian regression analysis, a 100 gene signature representative of ES activity in lung adenocarcinoma was developed and validated in a leave-one-out-analysis.
  • GSEA identified gene sets significantly represented in the ES signature: signature of neoplastic transformation, signature of undifferentiated cancer, BRCA pathway, and fibroblast serum response pathway, all associated with cancer invasiveness.
  • The ES signature was not prognostic in prostate, ovarian, or breast adenocarcinomas.
  • Lung tumors (N=634) and adenocarcinoma cell lines (N=31) with ES were more resistant to cisplatin (p<0.0001 and p=0.0063, respectively).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964049.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Tominaga E, Tsuda H, Arao T, Nishimura S, Chiyoda T, Nomura H, Kataoka F, Susumu N, Aoki D, Nishio K: Use of amplification of the 8q24 and 20q11-13 loci to predict progression-free survival of advanced epithelial ovarian cancer patients receiving standard therapy. J Clin Oncol; 2009 May 20;27(15_suppl):e16526

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of amplification of the 8q24 and 20q11-13 loci to predict progression-free survival of advanced epithelial ovarian cancer patients receiving standard therapy.
  • : e16526 Background: The purpose of this study was to identify genes that predict the progression free survival (PFS) of advanced epithelial ovarian cancer (aEOC) receiving standard therapy.
  • Thirty three aEOC patients (stage IIc: 4, III: 19, IV: 10; serous adenocarcinoma: 21, endometrioid adenocarcinoma: 5, undifferentiated: 7) were included in this array study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960791.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Collino F, Revelli A, Massobrio M, Katsaros D, Schmitt-Ney M, Camussi G, Bussolati B: Epithelial-mesenchymal transition of ovarian tumor cells induces an angiogenic monocyte cell population. Exp Cell Res; 2009 Oct 15;315(17):2982-94
Hazardous Substances Data Bank. HYDROCORTISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelial-mesenchymal transition of ovarian tumor cells induces an angiogenic monocyte cell population.
  • We found a CD14(+)/KDR(+) angiogenic monocyte population in undifferentiated ovarian tumors, significantly increased in the corresponding tumor metastasis.
  • In vitro, monocyte differentiation into CD14(+)/KDR(+) cells was induced by conditioned media from the primary ovarian tumor cells expressing a mesenchymal phenotype.
  • In contrast, the ovarian tumor cell line SKOV3 expressing an epithelial phenotype was unable to stimulate the differentiation of monocytes into CD14(+)/KDR(+) cells.
  • The obtained CD14(+)/KDR(+) cell population showed the expression of endothelial markers, increased the formation of capillary-like structures by endothelial cells and promoted the migration of ovarian tumor cells in vitro.
  • In conclusion, we showed that the epithelial-mesenchymal transition of ovarian tumor cells induced differentiation of monocytes into the pro-angiogenic CD14(+)/KDR(+) population and thus it may provide a tumor microenvironment that favours vasculogenesis and metastatization of the ovarian cancer.
  • [MeSH-major] Monocytes / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Aged. Antigens, CD / analysis. Antigens, CD14 / analysis. Cell Differentiation. Cell Division / drug effects. Cell Line, Tumor. Epidermal Growth Factor / pharmacology. Epithelial Cells / pathology. Female. Flow Cytometry. Humans. Hydrocortisone / pharmacology. Mesoderm / pathology. Middle Aged. Neoplasm Metastasis. Neovascularization, Pathologic / pathology. Ovarian Diseases / pathology. Ovarian Diseases / surgery

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19538958.001).
  • [ISSN] 1090-2422
  • [Journal-full-title] Experimental cell research
  • [ISO-abbreviation] Exp. Cell Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD14; 62229-50-9 / Epidermal Growth Factor; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


18. Chan JK, Hamilton CA, Anderson EM, Cheung MK, Baker J, Husain A, Teng NN, Kong CS, Negrin RS: A novel technique for the enrichment of primary ovarian cancer cells. Am J Obstet Gynecol; 2007 Nov;197(5):507.e1-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel technique for the enrichment of primary ovarian cancer cells.
  • OBJECTIVE: Primary cancer cells that are extracted from ovarian tumors can serve as an optimal substrate to study the biologic characteristics of ovarian cancer.
  • We describe an efficient and effective method of enriching ovarian tumor cells from ascitic fluid using an immunomagnetic-based method.
  • Epithelial ovarian cancer cells were labeled magnetically with monoclonal human epithelial antigen-125 that is conjugated to microbeads.
  • RESULTS: Peritoneal ascites specimens were obtained from 6 patients with ovarian cancer.
  • Three patients had papillary serous carcinoma; 2 patients had clear cell carcinoma, and 1 patient had an undifferentiated adenocarcinoma.
  • CONCLUSION: The immunomagnetic cell separation technique is an efficient and effective method for isolating and purifying ovarian tumor cells from ascites.
  • [MeSH-major] Adenocarcinoma / diagnosis. Ascitic Fluid / cytology. Immunomagnetic Separation / methods. Ovarian Neoplasms / diagnosis. Tumor Cells, Cultured / cytology
  • [MeSH-minor] Adenocarcinoma, Clear Cell / diagnosis. Adenocarcinoma, Papillary / diagnosis. Aged. Biomarkers, Tumor. Female. Flow Cytometry. Humans. Middle Aged

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17980191.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / human epithelial antigen-125
  •  go-up   go-down


19. Pulay T, Baki M, Bodoky G, Dank M, Cseh J, Csejtei A, Csömör S, Erfán J, Esik O, Faluhelyi Z, Izsó J, Hernádi Z, Kammerer K, Magyar T, Mayer A, Megyery E, Moskovits K, Pécsi L, Pikó B, Pintér T, Ruzsa A, Szánthó A, Szántó I, Szántó J, Szucs M, Tálos Z, Thurzó L, Kásler M: [The results of ovarian cancer therapy in the Hungarian Centers in 2002-2003]. Orv Hetil; 2006 Dec 31;147(52):2493-500
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The results of ovarian cancer therapy in the Hungarian Centers in 2002-2003].
  • Authors presented data of treatment results and course of disease in 487 ovarian cancer patients treated by primary surgery and paclitaxel-carboplatin combination chemotherapy between July 1, 2002 and December 31, 2003.
  • Distribution of their histological diagnosis was as 69.6% serous, 10.7% mucinous, 5.1% endometrial and 4.7% undifferentiated carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / therapy. Ovarian Neoplasms / therapy. Ovariectomy
  • [MeSH-minor] Adenocarcinoma, Mucinous / therapy. Adult. Aged. Brenner Tumor / therapy. Carboplatin / administration & dosage. Carcinoma, Endometrioid / therapy. Chemotherapy, Adjuvant. Cystadenocarcinoma, Serous / therapy. Drug Administration Schedule. Female. Humans. Hungary / epidemiology. Middle Aged. Paclitaxel / administration & dosage. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17294573.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


20. Waldstrøm M, Grove A: Immunohistochemical expression of wilms tumor gene protein in different histologic subtypes of ovarian carcinomas. Arch Pathol Lab Med; 2005 Jan;129(1):85-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of wilms tumor gene protein in different histologic subtypes of ovarian carcinomas.
  • CONTEXT: Immunohistochemical expression of Wilms tumor gene protein (WT1) has previously been described in primary ovarian carcinomas.
  • OBJECTIVE: To evaluate differences in WT1 expression among different histologic subtypes of ovarian carcinomas and the correlation to the histologic grade.
  • DESIGN: Ninety-one primary ovarian carcinomas were reviewed, and 1 representative formalin-fixed and paraffin-embedded tissue block was selected.
  • The lone malignant Brenner tumor and 3 (60%) of 5 undifferentiated carcinomas included in the study were also negative.
  • CONCLUSION: The present study demonstrates differences in immunohistochemical expression of WT1 among different histologic subtypes of primary ovarian carcinomas.
  • [MeSH-major] Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Mucinous / genetics. Brenner Tumor / genetics. Carcinoma, Endometrioid / genetics. Gene Expression Regulation, Neoplastic / genetics. Immunohistochemistry / methods. Ovarian Neoplasms / genetics. WT1 Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15628914.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / WT1 Proteins
  •  go-up   go-down


21. Crist KA, Zhang Z, You M, Gunning WT, Conran PB, Steele VE, Lubet RA: Characterization of rat ovarian adenocarcinomas developed in response to direct instillation of 7,12-dimethylbenz[a]anthracene (DMBA) coated suture. Carcinogenesis; 2005 May;26(5):951-7
Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of rat ovarian adenocarcinomas developed in response to direct instillation of 7,12-dimethylbenz[a]anthracene (DMBA) coated suture.
  • Human ovarian cancer is predominantly of epithelial cell origin (>90% of malignant tumors) and most often presents at an advanced stage with poor prognosis.
  • Most animal models of ovarian carcinoma yield thecal/granulosa cell tumors, rather than adenocarcinomas.
  • Induction of adenocarcinoma in 10-45% of rats following an ovarian implantation of 7,12-dimethylbenz[a]anthracene (DMBA) coated silk suture has been reported.
  • Here, DMBA of 99% purity was melted at 124 degrees C to impregnate a 1 cm length of sterile suture for direct ovarian implantation in Wistar Furth rats at 7 weeks of age.
  • Ovarian tumors in DMBA-treated rats were first noted at 26 weeks post implantation reaching a cumulative tumor incidence of 77% (23/30) at 52 weeks.
  • Tumor histology was distributed as well differentiated adenocarcinoma (1/23), poorly differentiated adenocarcinoma (8/23), thecal/granulosa cell tumor (8/23), undifferentiated sarcoma (5/23) and one undifferentiated carcinoma with no adeno character.
  • Adenocarcinomas appeared to originate from the ovarian surface epithelium, with focal papillary extension into cystic space.
  • [MeSH-major] 9,10-Dimethyl-1,2-benzanthracene / pharmacology. Adenocarcinoma / chemically induced. Carcinogens / pharmacology. Ovarian Neoplasms / chemically induced

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15695234.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CN / N01-CN-05103
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carcinogens; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene
  •  go-up   go-down


22. Kalir T, Rahaman J, Hagopian G, Demopoulos R, Cohen C, Burstein DE: Immunohistochemical detection of glucose transporter GLUT1 in benign and malignant fallopian tube epithelia, with comparison to ovarian carcinomas. Arch Pathol Lab Med; 2005 May;129(5):651-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical detection of glucose transporter GLUT1 in benign and malignant fallopian tube epithelia, with comparison to ovarian carcinomas.
  • DESIGN: One hundred two routinely fixed and processed archival specimens (36 benign fallopian tubes, 29 primary tubal adenocarcinomas, and 37 primary ovarian adenocarcinomas) were immunostained with rabbit anti-GLUT1 and developed with streptavidin-biotin/diaminobenzidine.
  • Of the 6 nonstaining tubal carcinomas, 3 were undifferentiated.
  • On average, GLUT1 staining in primary fallopian tube cancers was less extensive than in primary ovarian adenocarcinomas.
  • The difference in extent of GLUT1 staining between primary tubal and primary ovarian serous adenocarcinomas is discussed.
  • [MeSH-major] Adenocarcinoma / metabolism. Fallopian Tube Neoplasms / metabolism. Fallopian Tubes / metabolism. Immunohistochemistry / methods. Monosaccharide Transport Proteins / metabolism. Ovarian Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15859637.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucose Transporter Type 1; 0 / Monosaccharide Transport Proteins; 0 / SLC2A1 protein, human
  •  go-up   go-down


23. Wang H, Rosen DG, Wang H, Fuller GN, Zhang W, Liu J: Insulin-like growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types. Mod Pathol; 2006 Sep;19(9):1149-56
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insulin-like growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types.
  • Overexpression of IGFBP2 and IGFBP5 contributes to the invasiveness and progression of several human cancers, but their role and clinical significance in ovarian cancer has not been investigated in detail.
  • The other comprising 441 ovarian cancers of different histologic types linked to a clinicopathologic database.
  • They were differentially expressed in different types of ovarian carcinomas, being more often expressed at high levels in high-grade serous carcinoma, malignant mixed mullerian tumors and undifferentiated carcinoma, and more often expressed at low levels or not at all in clear cell and mucinous carcinomas.
  • We concluded that IGFBP2 and IGFBP5 might play a role in the development of high-grade ovarian serous carcinoma, but not in mucinous or clear cell ovarian carcinomas.
  • [MeSH-major] Carcinoma / metabolism. Insulin-Like Growth Factor Binding Protein 2 / metabolism. Insulin-Like Growth Factor Binding Protein 5 / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / mortality. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / pathology. Biomarkers, Tumor / metabolism. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / mortality. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / mortality. Cystadenocarcinoma, Serous / pathology. Female. Fluorescent Antibody Technique, Indirect. Humans. Image Processing, Computer-Assisted. Immunoenzyme Techniques. Neoplasm Staging. Survival Rate. Tissue Array Analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published online 26 May 2006.
  • (PMID = 16729015.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Insulin-Like Growth Factor Binding Protein 2; 0 / Insulin-Like Growth Factor Binding Protein 5
  •  go-up   go-down


24. Rask K, Zhu Y, Wang W, Hedin L, Sundfeldt K: Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression. Mol Cancer; 2006;5:62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression.
  • The present study investigated the pathway for PGE2-synthesis and signalling in ovarian tumourigenesis by analysing specimen from normal ovaries (n = 18), benign (B) (n = 8), borderline type (BL) (n = 6) and malignant tumours (AC) (n = 22).
  • Increased expressions were also observed for COX-1, mPGES-1 and EP-1 which all were significantly (p < 0.05) augmented in less differentiated AC (grades: moderately-, poorly- and undifferentiated).
  • IHC revealed staining of the tumour cells, but also increase of COX-1, COX-2, mPGES-1 and EP1-2 in the stromal compartment of AC (grades: moderately-, poorly- and undifferentiated).
  • CONCLUSION: The increases of COX-1, COX-2, mPGES-1 and EP1-2 in epithelial ovarian cancer, supports the hypothesis that PGE2-synthesis and signalling are of importance for malignant transformation and progression.
  • [MeSH-major] Dinoprostone / biosynthesis. Ovarian Neoplasms / metabolism. Signal Transduction / physiology
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Cyclooxygenase 1 / metabolism. Cyclooxygenase 2 / metabolism. Densitometry. Disease Progression. Epithelial Cells / pathology. Female. Humans. Immunoblotting. Immunohistochemistry. Intramolecular Oxidoreductases / metabolism. Neoplasm Staging. Ovary / metabolism. Receptors, Prostaglandin E / metabolism

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Soc Gynecol Investig. 2002 May-Jun;9(3):168-73 [12009392.001]
  • [Cites] J Environ Pathol Toxicol Oncol. 2002;21(2):149-53 [12086401.001]
  • [Cites] Ann Oncol. 2002 Aug;13(8):1205-11 [12181243.001]
  • [Cites] J Reprod Immunol. 2002 Oct-Nov;57(1-2):47-60 [12385833.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):906-11 [12615701.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1423-9 [14508829.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1298-304 [14520463.001]
  • [Cites] Prog Lipid Res. 2004 Jan;43(1):3-35 [14636669.001]
  • [Cites] Oncogene. 2003 Nov 27;22(54):8653-61 [14647459.001]
  • [Cites] Cancer. 2003 Dec 15;98(12):2607-23 [14669280.001]
  • [Cites] Oncol Rep. 2004 Feb;11(2):309-13 [14719060.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):538-45 [14760075.001]
  • [Cites] Gynecol Oncol. 2004 Feb;92(2):622-7 [14766256.001]
  • [Cites] Clin Cancer Res. 2004 Jul 15;10(14):4670-9 [15269139.001]
  • [Cites] Acta Obstet Gynecol Scand. 2004 Sep;83(9):783-95 [15315588.001]
  • [Cites] Reproduction. 2004 Nov;128(5):607-14 [15509706.001]
  • [Cites] Lancet. 1971 Jul 17;2(7716):163 [4104488.001]
  • [Cites] Gynecol Oncol. 1983 Dec;16(3):340-5 [6360817.001]
  • [Cites] Gynecol Obstet Invest. 1984;18(5):225-9 [6396175.001]
  • [Cites] Prostaglandins. 1985 May;29(5):665-72 [3859890.001]
  • [Cites] Int J Cancer. 1997 Jun 20;74(3):275-80 [9221804.001]
  • [Cites] J Histochem Cytochem. 1998 Jan;46(1):77-84 [9405496.001]
  • [Cites] Br J Cancer. 1999 Mar;79(7-8):1240-8 [10098766.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10501-6 [10468638.001]
  • [Cites] J Natl Cancer Inst. 1999 Sep 1;91(17):1459-67 [10469746.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):332-7 [15549095.001]
  • [Cites] Br J Cancer. 2005 May 23;92(10):1927-33 [15870720.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2005 Aug;73(2):103-11 [15963707.001]
  • [Cites] Oncogene. 2005 Dec 1;24(54):7991-8002 [16044148.001]
  • [Cites] Nucleic Acids Res. 2006;34(1):217-31 [16397300.001]
  • [Cites] Int J Cancer. 2006 Apr 15;118(8):1884-91 [16287068.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):130-40 [16491072.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2527-31 [16510568.001]
  • [Cites] Curr Pharm Des. 2006;12(8):943-54 [16533161.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Am J Obstet Gynecol. 2005 Mar;192(3):819-25 [15746677.001]
  • [Cites] Oncol Rep. 2005 Apr;13(4):559-83 [15756426.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2234-42 [15781636.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3735-44 [15867369.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3250-6 [15867220.001]
  • [Cites] J Reprod Fertil. 2000 Mar;118(2):375-85 [10864803.001]
  • [Cites] Epidemiology. 2000 Mar;11(2):111-7 [11021606.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):849-53 [11238034.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2001;41:661-90 [11264472.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2328-34 [11280806.001]
  • [Cites] Endocr Rev. 2001 Apr;22(2):255-88 [11294827.001]
  • [Cites] Int J Mol Med. 2001 Jul;8(1):31-6 [11408945.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2496-504 [11489832.001]
  • [Cites] Nat Med. 2001 Sep;7(9):1048-51 [11533709.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7305-9 [11585770.001]
  • [Cites] Int J Mol Med. 2001 Dec;8(6):603-6 [11712072.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):202-9 [11801560.001]
  • [Cites] Annu Rev Physiol. 2002;64:69-92 [11826264.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):893-903 [11891188.001]
  • (PMID = 17107625.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Prostaglandin E; EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.99.3 / prostaglandin-E synthase; K7Q1JQR04M / Dinoprostone
  • [Other-IDs] NLM/ PMC1657027
  •  go-up   go-down


25. Papathanasiou K, Tolikas A, Dovas D, Kostopoulou E, Fragkedakis N, Tzafettas J: Simultaneously detected primary malignant tumors of ovary and endometrium with unusual histology. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1191-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A case of a mucinous adenocarcinoma of the ovary with a synchronous endometroid tumor of the endometrium with focal features of undifferentiated carcinoma and deep myometrial invasion is reported.
  • A review of the literature revealed that our case is interesting in view of the fact that simultaneous presentation of primary ovarian and endometrial neoplasms is rare and usually related to low-stage ovarian lesions and well-differentiated and superficial endometrial carcinomas in contrast to our case with the focal features of undifferentiated carcinoma and the deep myometrial invasion.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343211.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Khunamornpong S, Lerwill MF, Siriaunkgul S, Suprasert P, Pojchamarnwiputh S, Chiangmai WN, Young RH: Carcinoma of extrahepatic bile ducts and gallbladder metastatic to the ovary: a report of 16 cases. Int J Gynecol Pathol; 2008 Jul;27(3):366-79
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Information on ovarian metastasis of carcinoma of the extrahepatic bile ducts and gallbladder is limited.
  • The patients ranged from 21 to 87 years (mean, 59 years); 7 presented to gynecologists with nonspecific pelvic symptoms similar to primary ovarian neoplasms.
  • The primary tumor was identified before the detection of the ovarian lesions in 5 cases, was simultaneously detected with the ovarian metastases in 9, and was diagnosed postoperatively in 2.
  • All but one case had bilateral ovarian involvement.
  • The thirty-one ovarian lesions included twenty-nine grossly abnormal ovaries that were enlarged (range, 3.0-16.5 cm, mean, 9.4 cm) and 2 ovaries with only microscopic involvement.
  • Microscopically, ovarian surface implants were seen in 66%, multinodular growth in 58%, and infiltrative stromal invasion in 81%.
  • Mucinous epithelial differentiation was seen in 81%, sometimes with foci of benign-like or borderline-like epithelium simulating primary ovarian mucinous neoplasia.
  • Nonmucinous carcinomatous components included adenocarcinoma with high-grade endometrioid-like morphology in 2 cases, papillary adenocarcinoma simulating mixed müllerian epithelial adenocarcinoma in 1, and undifferentiated carcinoma in 2.
  • Although the diagnosis of a metastatic tumor to the ovary is possible in most of the cases based on standard diagnostic criteria, problems in the differential diagnosis may be posed by morphologic patterns that overlap strikingly with primary ovarian neoplasms, benign, borderline, and malignant, as discussed herein.
  • [MeSH-major] Adenocarcinoma / pathology. Bile Duct Neoplasms / pathology. Gallbladder Neoplasms / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580314.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Yang CQ, Zhang ZC, Yu Q, Pang JX: [Clinicopathologic characteristics of metastatic carcinomas to spleen]. Zhonghua Bing Li Xue Za Zhi; 2006 May;35(5):281-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On the other hand, primary ovarian tumor was commonly seen in females (2/4).
  • Histologically, undifferentiated carcinoma of lung was frequently encountered (25.0%, 4/16), including 3 cases of small cell undifferentiated carcinoma and 1 case of large cell undifferentiated carcinoma.
  • Other histologic tumor types included bronchioloalveolar carcinoma (2 cases), colonic adenocarcinoma (2 cases), ovarian serous papillary adenocarcinoma (2 cases), and prostatic adenocarcinoma (2 cases).
  • The commonest histologic tumor type found in male patients was pulmonary undifferentiated carcinoma.
  • Examples of these tumors included small cell undifferentiated carcinoma (3 cases), pulmonary adenocarcinoma (1 case) and prostatic adenocarcinoma (1 case).
  • [MeSH-major] Lung Neoplasms / pathology. Ovarian Neoplasms / pathology. Spleen / pathology. Splenic Neoplasms / secondary
  • [MeSH-minor] Adenocarcinoma / secondary. Adenocarcinoma, Bronchiolo-Alveolar / secondary. Aged. Aged, 80 and over. Carcinoma, Small Cell / secondary. Colonic Neoplasms / pathology. Cystadenocarcinoma, Serous / secondary. Female. Humans. Male. Middle Aged. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16776999.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


28. Brun JL, Randriambelomanana J, Cherier L, Lafon ME, Trufflandier N, Le Bail B: Lymphoepithelioma-like carcinoma of the ovary: a case report and review of the literature. Int J Gynecol Pathol; 2010 Sep;29(5):427-31
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cytoreductive surgery was performed to remove a left ovarian neoplasm and multiple involved lymph nodes.
  • The tumor was a mixed poorly undifferentiated ovarian carcinoma consisting of 95% LELC and 5% moderately differentiated serous adenocarcinoma.
  • To our knowledge, this is the second case of ovarian LELC and the first description of the native tumor before chemotherapy.
  • However, clinicians and pathologists should be aware that ovarian tumors with massive involvement of lymph nodes and no peritoneal carcinomatosis are suggestive of such a diagnosis and that prognosis is relatively good.
  • [MeSH-major] Carcinoma / pathology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20736767.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


29. Zamecnik M, Voltr L, Stuk J, Chlumska A: Krukenberg tumor with yolk sac tumor differentiation. Int J Gynecol Pathol; 2008 Apr;27(2):223-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary tumor was in the gastric antrum, and it showed morphology of poorly differentiated adenocarcinoma with diffuse and solid growth pattern.
  • In the ovarian metastases, YST element showed microcystic/reticular and solid patterns, whereas the adenocarcinoma component was of diffuse type with signet ring cells and with some undifferentiated areas.
  • [MeSH-major] Endodermal Sinus Tumor / pathology. Krukenberg Tumor / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Yolk sac tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18317220.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Keratin-20; 0 / Keratin-7
  •  go-up   go-down


30. Asensio N, Luis A, Costa I, Oliveira J, Vaz F: Meningeal carcinomatosis and uterine carcinoma: three different clinical settings and review of the literature. Int J Gynecol Cancer; 2009 Jan;19(1):168-72
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Leptomeningeal carcinomatosis is a rare metastatic event in gynecological neoplasias, and most cases occur in ovarian cancer.
  • RESULTS AND DISCUSSION: Leptomeningeal carcinomatosis is usually diagnosed late in the course of the disease, and most reports concern ovarian cancer patients.
  • The case we report of endometrial carcinoma, unique in the literature, is a serous adenocarcinoma.
  • CONCLUSIONS: A high index of suspicion is necessary, and leptomeningeal carcinomatosis should be considered in patients with unexplained neurologic symptoms whose gynecologic tumors are poorly undifferentiated or have a serous component.
  • [MeSH-major] Cystadenocarcinoma, Serous / secondary. Endometrial Neoplasms / pathology. Meningeal Neoplasms / secondary. Ovarian Neoplasms / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19258961.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 31
  •  go-up   go-down


31. Garg K, Shih K, Barakat R, Zhou Q, Iasonos A, Soslow RA: Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset. Am J Surg Pathol; 2009 Dec;33(12):1869-77
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recognition of features that might discourage conservative management and ovarian preservation are currently poorly characterized.
  • Five (7%) were undifferentiated carcinomas.
  • A significant number of patients also had synchronous ovarian carcinomas (9 of 70, 13%), predominantly endometrioid (7 of 9), whereas 2 were ovarian clear cell carcinomas.
  • They frequently showed tumor characteristics associated with microsatellite instability, including tumor infiltrating lymphocytes, undifferentiated or dedifferentiated histology, and lower uterine segment origin.
  • None of the cases with synchronous ovarian and endometrial endometrioid carcinomas showed loss of MMR proteins, whereas 1 of 2 ECs with synchronous CCC of ovary showed loss of MSH2/MSH6.As young women with endometrioid carcinomas who show loss of mismatch proteins are at risk for high-grade tumors with worse clinical outcomes and lower estrogen receptor/progesterone receptor expression, they may not be appropriate candidates for conservative management.
  • Although young EC patients are at increased risk for synchronous endometrioid ovarian carcinomas, this does not seem to be associated with MMR loss.
  • [MeSH-major] Adenocarcinoma, Clear Cell / enzymology. Carcinoma, Endometrioid / enzymology. DNA Mismatch Repair. DNA Repair Enzymes / analysis. Endometrial Neoplasms / enzymology. Neoplasms, Multiple Primary. Ovarian Neoplasms / enzymology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19898223.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA008748
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / DNA-Binding Proteins; 0 / G-T mismatch-binding protein; 0 / MLH1 protein, human; 0 / Nuclear Proteins; EC 3.6.1.- / Adenosine Triphosphatases; EC 3.6.1.- / PMS2 protein, human; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


32. Ohtsuki S, Kamoi M, Watanabe Y, Suzuki H, Hori S, Terasaki T: Correlation of induction of ATP binding cassette transporter A5 (ABCA5) and ABCB1 mRNAs with differentiation state of human colon tumor. Biol Pharm Bull; 2007 Jun;30(6):1144-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ABCA5 mRNA was detected in poorly differentiated colon adenocarcinoma (GI-112) and undifferentiated ovarian carcinoma (GI-102), but not in normal colon.
  • In contrast, ABCC1 and ABCA2 mRNAs, but not ABCA5 or ABCB1 mRNA, were detected in well differentiated colon adenocarcinoma (CX-1).
  • [MeSH-major] ATP-Binding Cassette Transporters / metabolism. Adenocarcinoma / metabolism. Colonic Neoplasms / metabolism. Organic Anion Transporters / metabolism. RNA, Messenger / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17541169.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / ABCA5 protein, human; 0 / ABCB1 protein, human; 0 / DNA, Complementary; 0 / Organic Anion Transporters; 0 / P-Glycoprotein; 0 / P-Glycoproteins; 0 / RNA, Messenger
  •  go-up   go-down


33. Nakanuma Y, Sato Y, Harada K, Sasaki M, Xu J, Ikeda H: Pathological classification of intrahepatic cholangiocarcinoma based on a new concept. World J Hepatol; 2010 Dec 27;2(12):419-27

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To date, ICC was largely classified into adenocarcinoma and rare variants.
  • The former is a tubular or micropapillary adenocarcinoma while the latter involves the intrahepatic large bile duct.
  • Biliary mucinous cystic neoplasm with ovarian-like stroma in its wall is different from IPNB, particularly IPNB showing cystic dilatation of the affected ducts.
  • Rare variants of ICC include squamous/adenosquamous cell carcinoma, mucinous/signet ring cell carcinoma, clear cell type, undifferentiated type, neuroendocrine carcinoma and so on.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 2008 Jun;215(2):175-83 [18393368.001]
  • [Cites] Mod Pathol. 2001 May;14(5):527-32 [11353065.001]
  • [Cites] J Clin Gastroenterol. 1994 Jun;18(4):335-42 [8071522.001]
  • [Cites] Hepatology. 2004 Jun;39(6):1739-45 [15185318.001]
  • [Cites] Hepatology. 2006 Nov;44(5):1333-43 [17058219.001]
  • [Cites] J Hepatol. 2006 Feb;44(2):350-8 [16360234.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2003;10(4):288-91 [14598147.001]
  • [Cites] Hepatol Res. 2007 Oct;37 Suppl 3:S478-86 [17931207.001]
  • [Cites] Histopathology. 1980 Jul;4(4):391-400 [6253379.001]
  • [Cites] Hepatology. 2001 Oct;34(4 Pt 1):651-8 [11584359.001]
  • [Cites] World J Hepatol. 2009 Oct 31;1(1):35-42 [21160963.001]
  • [Cites] Lab Invest. 2009 Nov;89(11):1261-74 [19721413.001]
  • [Cites] Hepatol Res. 2008 Apr;38(4):325-34 [18093122.001]
  • [Cites] J Hepatol. 2006 Dec;45(6):856-67 [17030071.001]
  • [Cites] Microsc Res Tech. 1997 Sep 15;38(6):552-70 [9330346.001]
  • [Cites] Am J Pathol. 2009 Mar;174(3):829-41 [19218340.001]
  • [Cites] Mod Pathol. 2006 Sep;19(9):1243-54 [16741522.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2145-9 [9610693.001]
  • [Cites] Cancer. 1977 Jan;39(1):232-46 [64293.001]
  • [Cites] Pathol Int. 2010 Jun;60(6):419-29 [20518896.001]
  • [Cites] Pathol Int. 2010 Jul;60(7):516-9 [20594273.001]
  • [Cites] Mod Pathol. 2007 Jun;20(6):701-9 [17431410.001]
  • [Cites] Curr Gastroenterol Rep. 2006 Feb;8(1):30-7 [16510032.001]
  • [Cites] Pathol Int. 2005 Apr;55(4):180-8 [15826244.001]
  • [Cites] Am J Surg Pathol. 2004 Sep;28(9):1193-203 [15316319.001]
  • [Cites] Hum Pathol. 2003 Dec;34(12):1337-44 [14691921.001]
  • [Cites] Histopathology. 2007 Sep;51(3):390-400 [17553067.001]
  • (PMID = 21191517.001).
  • [ISSN] 1948-5182
  • [Journal-full-title] World journal of hepatology
  • [ISO-abbreviation] World J Hepatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC3010511
  • [Keywords] NOTNLM ; Adenocarcinoma / Bile duct / Bile ductule / Intraductal neoplasm / Intrahepatic cholangiocarcinoma
  •  go-up   go-down


34. Pejcić I, Vrbić S, Filipović S, Sćekić M, Petković I, Pejcić L, Djenić N: [Significance of serum tumor markers monitoring metastases in carcinomas of unknown primary site]. Vojnosanit Pregl; 2010 Sep;67(9):723-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Following the routine light microscopy, all histological findings were classified into one of the following three groups: plano-cellular carcinoma--8 patients; adenocarcinoma--33 patients; unclassifiable (undifferentiated) carcinoma--22 patients.
  • In all the cases we evaluated 8 serum tumor markers: alpha-fetoproteins (AFP), chronic gonadotrophin beta submit, human (beta-HCG), neuron specific enolase (NSE), marker of malignant ovarian tumors (CA 125), prostate-specific antigene (PSA), marker of malignant brest tumor (CA 15-3), marker of malignant pancreas tumor and gastrointestinal tumor (Ca 19-9), carcinoembryonic antigen (CEA) at the time of diagnosis.
  • [MeSH-major] Adenocarcinoma / secondary. Biomarkers, Tumor / blood. Carcinoma / secondary. Carcinoma, Squamous Cell / secondary. Neoplasms, Unknown Primary / pathology


35. Kuroda N, Moriki T, Oguri H, Maeda N, Toi M, Miyazaki E, Hiroi M, Fukaya T, Enzan H: Malignant müllerian mixed tumor (carcinosarcoma) of the fallopian tube: an immunohistochemical study of neoplastic cells. APMIS; 2005 Sep;113(9):643-6
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Salpingo-oophorectomy and hysterectomy were performed due to suspicion of ovarian cancer.
  • Histologically, proliferation of undifferentiated neoplastic cells with marked cytological atypia predominated in the tumor.
  • Proliferation of rhabdomyoblastic cells or spindle cells, as well as adenocarcinoma arising from the mucosa of the fallopian tube, was observed.
  • CD10 was expressed in adenocarcinoma, undifferentiated, spindle and rhabdomyoblastic cells.
  • Undifferentiated and spindle neoplastic cells were focally positive for ASMA and negative for h-caldesmon.
  • Finally, our preliminary report suggests that MMMT of the fallopian tube may contain immature smooth muscle cells or cells with the myofibroblast-like immunohistochemical phenotype in the undifferentiated component.

  • Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16218942.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


36. Kietpeerakool C, Suprasert P, Srisomboon J, Pantusart A: Primary carcinoma of the fallopian tube: A clinicopathologic analysis of 27 patients. J Med Assoc Thai; 2005 Oct;88(10):1338-43

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histology were serous adenocarcinoma (70.4%), endometrioid adenocarcinoma (22.2%), undifferentiated adenocarcinoma (3.77%) and carcinosarcoma (3.7%).
  • As opposed to epithelial ovarian cancer, the majority of women in the present study were in the early stages of the disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16519376.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


37. Franco-Hernandez C, Martinez-Glez V, Arjona D, de Campos JM, Isla A, Gutierrez M, Vaquero J, Rey JA: EGFR sequence variations and real-time quantitative polymerase chain reaction analysis of gene dosage in brain metastases of solid tumors. Cancer Genet Cytogenet; 2007 Feb;173(1):63-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The metastases derived from malignant melanoma (three cases), lung carcinoma (six cases), breast carcinoma (three cases), ovarian carcinoma (two cases), and one each from colon, kidney, bladder, and undifferentiated carcinoma.
  • These mutations presented in lesions derived from kidney carcinoma and lung adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17284372.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down






Advertisement